Update your tester profile Login
  • Register with Our Database

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies. We will not share or sell this info with any third party. 

    Thanks for your interest, you'll find the intake form here

     

    Unfortunately at this time, Prism can not allow volunteers who live over 200 miles away to participate in research studies. If you live out of state or over 200 miles away please call

    Geoff at 651-641-2911 with questions. 

  • Refer Your Friends & Family to Participate

    Simply help us get the word out about Prism Clinical Research and we’ll give you $100 for every friend you refer that completes a study.

    It’s that easy! Make money with each referral, and there’s no limit to how many friends you can refer!

    Rules:

    • Subject must complete the study.
    • Subject may not be referred more than one time.
    • Subjects may not refer each other.
    • Subject must complete the study before payment can be received.
    • Subjects eligible for Referral: (1) Must not be in Prism Clinical Research database; (2) Must not have participated in any study at Prism.
    • In the event that a subject is referred by multiple people, the first person who referred will receive payment.
    • Eligibility will be determined by Prism. Prism reserves the right to revise or eliminate this program at any time without notice.

     

     

  • Diagnosed with Liver Impairment?

    Prism Research has upcoming studies for individuals diagnosed with liver impairment.  These studies will help determine how an investigational drug is broken down and removed from the body in volunteers with various degrees of liver impairment when compared to volunteers with normal liver function.

     

    If you or someone you know has been diagnosed with liver impairment and are interested in being considered for these studies, please contact Dayna at 651-724-5047 or register with our database and we will call you. Financial compensation for study participation ranges from $400-$3500.

     Contact Dayna 651-724-5047 or daynas@prismresearchinc.com

  • Study 1321 Cohort 10: Healthy Female and Male Participants
    Research Purpose: To evaluate the safety and tolerability of an investigational drug being developed for the treatment of certain inflammatory disorders.  The following will be evaluated:
    • How much of the investigational drug enters the blood stream, and is excreted in the stool, after a single dose in a fasted state
    • Assess changes in inflammatory mediators after a single dose in the fasted state.

    For information regarding this study contact Dayna at 651-724-5047 or daynas@prismresearchinc.com

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not breastfeeding, are not pregnant or planning to become pregnant are allowed to participate.  Women of child bearing potential must agree to take appropriate precautions to avoid pregnancy.

    Age

    18-55 years

    Weight/Body Mass Index (BMI)

    BMI between 18-32.0 kg/m²

    Tobacco/Nicotine Use

    No use of tobacco/nicotine containing products including electronic cigarettes more frequently than 5 cigarettes per day.  No tobacco/nicotine 1 week prior to screening and for the duration of the study.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor.

    Dietary Requirements

    Must be able and willing to eat/drink the following: eggs, pork products, gluten, dairy, potatoes, and fruit.

    Study Time Commitment:  Approximately 5 weeks (~35 days)

     

    Clinic Stay

    • One in-clinic stay of 5 nights/6 days

    Outpatient Visits

    • One follow-up outpatient visit

    Screenings Start: Tuesday, August 1st

    Compensation for participation time: Up to $1400.00

    For information regarding this study contact Dayna at 651-724-5047 or daynas@prismresearchinc.com

  • 1613 Part2: Healthy Males and Females

    Study 1613 Part 2: Healthy Female and Male Participants

     

    Research Purpose: To evaluate the safety and tolerability of an investigational drug being developed for the treatment of peanut allergy.

     *September Dates*

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not breastfeeding, are not pregnant or planning to become pregnant are allowed to participate.  Women on hormonal birth control are allowed to participate provided they use an approved secondary method of birth control.

    Age

    18-45 years

    Weight/Body Mass Index (BMI)

    Weight between 88 – 198 lbs. for women and between 110 – 220 lbs. for men. 

    BMI between 18-30 kg/m²

    Tobacco/Nicotine Use

    No use of tobacco/nicotine containing products including electronic cigarettes more frequently than 5 cigarettes per day prior to the study is allowed.  No tobacco/nicotine use is permitted for the duration of the study.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor.

     

     

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 8 weeks with 2 follow-up phone questionnaires 6 months apart.

    Clinic Stay

    • Participants will admit to Prism Clinical Research 1 time.
    • The in Clinic stay will last approximately 9 days (8 overnights)

    Outpatient Visits

    • There are 21 clinic visits following the discharge from the clinic.
    • End of study will be Day 35.
    • There will be 2 follow-up telephone questionnaires that will be performed approximately 6 months apart after completion of the clinic visits.

     

     

    Compensation for participation time: Up to $4695.00

     

    For information regarding this study contact Lindsay at 651-368-3360 or lindsayd@prismresearchinc.com

  • Study 1707: Healthy Males and Females

    Study 1707: Healthy Female and Male Participants

     

    Research Purpose: To evaluate the safety, tolerability and absorption rate of an investigational drug being developed for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD).

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not breastfeeding, are not pregnant or planning to become pregnant are allowed to participate.  Women must agree to practice a highly effective method of contraception during the course of the study.

    Age

    18-55 years

    Weight/Body Mass Index (BMI)

    Weight greater than 110lbs

    BMI between 18.5-30 kg/m²

    Tobacco/Nicotine Use

    Use of tobacco or tobacco containing products is not permitted. 

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor.

     

     

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 8 weeks

     

    Clinic Stay

    • Participants will admit to Prism Clinical Research 2 times.
    • Each in-clinic stay will last approximately 3 nights (4 days).

    Outpatient Visits

    • There are 2 outpatient visits (including the screening).

     

     

    Compensation for participation time: Up to $1,795.00

     

    For information regarding this study contact Lindsay at 651-368-3360 or lindsayd@prismresearchinc.com

  • Study 1710 Part 1: Individuals with Moderate Renal Impairment

    Research Purpose: To determine whether the investigational drug displays the clinical safety profile to support further development in patients with moderately impaired renal function.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women of non-childbearing potential are allowed to participate

    Age

    40-85 years of age

    Body Mass Index (BMI)

    Between 18-40 kg/m²

    Minimum Weight

    50 kg

    MDRD

    30-59 mL/min/1.73 m²

    Angiotensin receptor blocker (ARB)

    Must be on an ARB for at last a month prior to screening

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 11 weeks. 

    Clinic Stay

    • Participants will be confined at Prism Clinical Research one time during the study period for up to 16 days and (15 nights).

    Return Clinic Visits

    • There is one return clinic visit approximately 1 week after discharge.

     

    Phone Call

    • There is one Phone call approximately 30 days after your final return visit.

     

    Screenings begin: July 19th 2017

    Anticipated start date for Study 1710:  25 July 2017            

     

    Compensation for participation time: Up to $3725.00 if all clinic visits are completed.

                           

    For information regarding this study contact Kevin @: 651-724-5046 or kfitzgerald@prismresearchinc.com

     

  • Study 1620: Male and Female Participants with Nasal Polyps

    Research Purpose: Study 1620 is designed to determine the safety and tolerability of an investigational drug being developed for the treatment of Chronic Rhinosinusitis with Nasal Polyps.

    *Must be diagnosed with Nasal Polyps to participate in this study*


    For information regarding this study contact Dayna 651-724-5047 or daynas@prismresearchinc.com

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women may participate if they meet one of the following criteria: postmenopausal, hysterectomy and/or bilateral oophorectomy, medically confirmed ovarian failure, tubal ligation or bilateral salpingectomy.

    Age

    18-65 years

    Body Mass Index (BMI)

    Between 17.5 – 35.0 kg/m²

    Tobacco/Nicotine Use

    Must be willing to abstain from tobacco and/or nicotine containing products for 24 hours prior to dosing and during the clinic stay.

    Health History

    Must be healthy; with the exception of diagnosed nasal polyps and chronic rhinosinusitis.

    Restricted Medications

    All medications will be reviewed for inclusion prior to screening.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 12 months.

    Clinic Stay

    • Participants will admit to Prism Clinical Research one-time for 2 overnights

    Clinic Visits

    • There are up to 13 follow-up clinical visits

     

    Compensation for participation time:   Up to $1,860                           


    For information regarding this study contact Dayna 651-724-5047 or daynas@prismresearchinc.com

Trial Designs

Prism Clinical Research has experience conducting successful studies with the following trial designs:

  • Bioavailability and Bioequivalence

  • FIM SAD and MAD

  • PK/PD

  • Qt Interval

  • Drug Interaction

  • Food Effect

  • Food Intake/Obesity

  • Vaccines

  • Imaging trials

  • Biomarkers

  • Device

Please provide us with your contact information (below) and will get back to you as soon as possible.

If you have a general question, check Volunteer FAQ for an answer. If you're unsure of who to contact, please visit the Contact Us page.

Cancel